BlackDiamond Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.3M Buy
5,233
+190
+4% +$40.9K 0.52% 51
2026
Q1
$1.1M Buy
5,043
+65
+1% +$14.4K 0.53% 48
2025
Q4
$1.11M Buy
4,978
+2,820
+131% +$642K 0.54% 49
2025
Q3
$500K Buy
2,158
+47
+2% +$9.57K 0.27% 74
2025
Q2
$401K Buy
2,111
+228
+12% +$42.4K 0.23% 83
2025
Q1
$348K Sell
1,883
-394
-17% -$76.6K 0.23% 81
2024
Q4
$405K Buy
2,277
+109
+5% +$20K 0.23% 94
2024
Q3
$371K Buy
2,168
+228
+12% +$42.6K 0.22% 101
2024
Q2
$369K Buy
1,940
+413
+27% +$68.4K 0.24% 91
2024
Q1
$278K Sell
1,527
-24
-2% -$4.14K 0.2% 114
2023
Q4
$266K Buy
+1,551
New +$226K 0.2% 110
2023
Q2
Sell
-1,287
Closed -$212K 129
2023
Q1
$212K Buy
1,287
+20
+2% +$3.06K 0.22% 104
2022
Q4
$202K Buy
+1,267
New +$194K 0.23% 108

Other funds holding ABBV

BlackDiamond Wealth Management's ABBV Position: Q2 2026 in Review

BlackDiamond Wealth Management increased its AbbVie (ABBV) stake by 3.8% in Q2 2026, buying an estimated $40.9K and bringing the position to 5,233 shares worth $1.3M. The position accounts for 0.52% of the portfolio, ranked #51.

BlackDiamond Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 13 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • BlackDiamond Wealth Management held 5,233 shares of AbbVie worth $1.3M as of Q2 2026.
  • BlackDiamond Wealth Management bought 190 AbbVie shares in Q2 2026, an estimated $40.9K.
  • AbbVie made up 0.52% of BlackDiamond Wealth Management's portfolio in Q2 2026, its #51 holding.
  • BlackDiamond Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 13 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BlackDiamond Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.